Eton Pharmaceuticals, Inc. ETON
57.68
(1.81)
(3.04%)
as of 25 Sep
- Market cap
- $1.7B
- P/E
- 123×
Follow ETON
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 35.97% | (5.36%) | (18.19%) | (34.17%) |
+8 more TTM periods Free account |
|
| 11.67% | (1.62%) | (5.47%) | (9.52%) | ||
ROIC |
21.39% | 3.06% | (1.71%) | (10.23%) | |
Return on Tangible Assets |
53.25% | (15.63%) | (20.52%) | (23.77%) | |
Average Days of Receivables |
86.02 | 56.29 | 53.67 | 67.91 | |
Free Cash Flow per Share |
(0.30) | (0.28) | 0.38 | 0.78 | |
Free Cash Flow |
(8.39) | (7.70) | 10.18 | 21.01 | |
Capital Expenditures |
(23.52) | (23.54) | (0.34) | (0.30) | |
Piotroski F-Score |
6.00 | 5.00 | 5.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
14.94% | 19.55% | 12.73% | 23.52% | |
Accounts Receivable Turnover |
5.37 | 5.83 | 9.34 | 7.53 | |
Accounts Payable Turnover |
3.35 | 4.28 | 4.91 | 4.04 | |
Inventory Turnover |
2.62 | 2.80 | 2.43 | 3.64 | |
Average Days of Payables |
118.17 | 125.18 | 107.67 | 152.18 | |
Days of Inventory on Hand |
83.21 | 134.29 | 151.25 | 179.89 | |
Tax Rate |
0.00 | (0.01) | 0.01 | 0.03 | |
Research and Development Expense of Revenue |
5.45% | 9.75% | 9.71% | 7.27% | |
Selling, General and Administrative Expense of Revenue |
36.97% | 42.67% | 44.80% | 47.90% | |
Share Based Compensation of Revenue |
4.93% | 6.71% | 6.89% | 7.35% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.19 | (10.74) | (2.29) | (3.19) | |
Depreciation/Fixed assets |
14.70 | 12.59 | 14.54 | 16.81 | |
Capex/Depreciation |
(4.55) | (5.03) | (0.07) | (0.06) | |
Revenue per Share |
3.82 | 3.19 | 2.97 | 2.61 | |
Operating CF per Share |
0.55 | 0.58 | 0.39 | 0.79 | |
Capex per Share |
(0.85) | (0.86) | (0.01) | (0.01) | |
Capex to Sales |
0.22 | 0.27 | 0.00 | 0.00 | |
Net Profit Margin |
12.02% | (1.70%) | (5.75%) | (9.50%) |
Columns are period end dates